DFCI-BIDMC-CH CENTER FOR AIDS RESEARCH

DFCI-BIDMC-CH 艾滋病研究中心

• 批准号: 6534010
• 负责人: JOSEPH G SODROSKI
• 金额: $ 154.57万
• 依托单位: DANA-FARBER CANCER INST
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-09-15 至 2004-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6534010
• 关键词: AIDS; biomedical facility; human immunodeficiency virus 1

OVERALL DESCRIPTION (adapted from the application): This application proposes the establishment of the Dana-Farber Cancer Institute Beth Israel Deaconess Medical Center, and Children's Hospital (DFCI-BIDMC-CH) Center for AIDS Research (DFCI-BIDMC-CH CFAR). The DFCI-BIDMC-CH CFAR encompasses clinical and basic science research conducted at the Dana-Farber Cancer Institute Beth Israel Deaconess Medical Center, and Children's Hospital. The DFCI-BIDMC-CH CFAR is the product of the longstanding commitment of these institutions to AIDS research and patient care, and builds upon an existing Center for AIDS Research at the Dana-Farber Institute. The CFAR award would support the continuation or establishment of six scientific Core Facilities. The Administrative Core provides administrative support to: 1) the CFAR leadership, including the Executive Committee and five advisory committees; 2) the Development and Clinical Cores; 3) the Core Facilities; and 4) the CFAR membership. The Development Core will be utilized to enhance the CFAR research program by providing support for new investigators to develop AIDS-related research activities and for pilot projects to exploit innovative ideas and technology for AIDS research. The Biohazard Containment Core provides a Biosaftey Level 3 facility for the propagation and purification of human or simian immunodeficiency viruses for the interdisciplinary team of CFAR investigators. The purpose of the Animal Biohazaard Containment (ABC) Core Facility is to provide support for AIDS-related mouse work that requires biosafety levels 2 or 3 containment. The Molecular Biology Core Facility provides oligonucleotides and conjugated or unconjugated peptides on a charge-back basis. The cell culture facility is designed to provide large amounts of monoclonal antibodies and purified proteins to researchers for the use in AIDS related research. The major emphasis of the Clinical Core is to develop clinical AIDS research in the CFAR member institutions and the surrounding community. The Biostatistics Core supports consultation and collaboration on quantitative methods to investigators throughout the CFAR.

总体描述（改编自本申请）：本申请提出建立丹娜-法伯癌症研究所贝斯以色列女执事医疗中心和儿童医院（DFCI-BIDMC-CH）艾滋病研究中心（DFCI-BIDMC-CH CFAR）。 DFCI-BIDMC-CH CFAR包括在Dana-Farber癌症研究所Beth以色列女执事医疗中心和儿童医院进行的临床和基础科学研究。 DFCI-BIDMC-CH CFAR是这些机构长期致力于艾滋病研究和患者护理的产物，并建立在达纳法伯研究所现有的艾滋病研究中心的基础上。CFAR奖将支持继续或建立六个科学核心设施。行政核心为以下机构提供行政支持：1）CFAR领导层，包括执行委员会和五个咨询委员会; 2）开发和临床核心; 3）核心设施; 4）CFAR成员。开发核心将用于 加强CFAR研究计划，提供 支持新的研究人员开展与艾滋病有关的研究活动，并支持试点项目，利用艾滋病研究的创新思想和技术。 生物危害遏制核心为CFAR研究人员的跨学科团队提供了一个生物安全3级设施，用于人类或猿免疫缺陷病毒的繁殖和纯化。 动物生物危害控制（ABC）核心设施的目的是为需要生物安全2级或3级控制的艾滋病相关小鼠工作提供支持。 分子生物学核心设施以收费方式提供寡核苷酸和结合或未结合肽。 该细胞培养设施旨在为研究人员提供大量的单克隆抗体和纯化蛋白质，用于艾滋病相关研究。 临床核心的主要重点是在CFAR成员机构和周围社区开展艾滋病临床研究。 生物统计学核心支持 协商 和协作 对 定量方法 给整个CFAR的调查人员